# Checkpoint 28A Round 99 R7 Loop 5 Biotech / Healthcare / Medical Device

## Summary

Round 99 applies the R7 Loop 5 healthcare research pack as calibration material only.
It does not change production scoring, StageClassifier thresholds, or candidate generation.

The pack separates healthcare narratives into evidence families:

- CDMO capacity and US tariff-hedge capacity
- ADC / cell / gene manufacturing capability
- CRO funding-cycle sensitivity
- biosimilar commercialization, cash-pay access, and patent litigation
- GLP-1 commercialization, oral maintenance therapy, telehealth channels, and price-war risk
- gene therapy commercialization failure
- AI drug discovery and medical AI external validation
- remote medicine and behavioral telehealth unit economics
- medical-device export, dental implants, surgical robots, botulinum aesthetics, and safety overlays
- disclosure confidence caps when key terms are missing

Simple example: `FDA approval` can be Stage 1 or Stage 2 evidence, but it is not Stage 3-Green evidence by itself. The pack requires prescriptions, reimbursement, paid deployment, utilization, repeat procedures, consumables, OPM, FCF, or other commercialization proof before higher conviction.

## Implemented Files

- `src/e2r/sector/round99_r7_loop5_biotech_healthcare_device.py`
- `src/e2r/cli/build_round99_r7_loop5_report.py`
- `tests/test_round99_r7_loop5_biotech_healthcare_device.py`
- `data/e2r_case_library/cases_r7_loop5_round99.jsonl`
- `data/sector_taxonomy/score_weight_profiles_round99_r7_loop5_v5.csv`
- `output/e2r_round99_r7_loop5_biotech_healthcare_device/`

## Archetype Counts

- target_count: 27
- case_candidate_count: 17
- structural_success_count: 2
- success_candidate_count: 7
- stage4c_case_count: 8
- green_possible_count: 5
- watch_yellow_first_count: 11
- redteam_first_count: 11
- gate_only_target_count: 6

## New / Confirmed Archetypes

- `CDMO_ADC_CELL_GENE_CAPABILITY`
- `BIOSIMILAR_ACCESS_CASH_PAY`
- `GLP1_PRICE_WAR_OVERLAY`
- `DISCLOSURE_CONFIDENCE_CAP`

`DISCLOSURE_CONFIDENCE_CAP` is intentionally cap-only, not gate-only. Missing contract amount, term, counterparty, reimbursement, prescription, or fee fields should cap Stage 3 confidence, but the cap itself is not a separate positive or negative candidate generator.

## Case Pack Notes

The pack includes Samsung Biologics, Intuitive Surgical, Straumann, Lilly, Novo Nordisk, Hims, bluebird bio, Charles River, Teladoc, Recursion / Exscientia, Lunit, Amgen / Samsung Bioepis, and Botox counterfeit safety references.

Cases are calibration/evaluation records. They must not be used as production candidate-generation input.

## Guardrails

- Do not use case records as candidate-generation input.
- Do not invent prescriptions, reimbursement, capacity utilization, patient uptake, hospital adoption, cash runway, or stage prices.
- Do not treat approval, AI model AUC, external validation, TAM, pilot usage, or user growth as Green evidence alone.
- Do not apply Round 99 v5.0 score weights to production scoring yet.
- Keep GLP-1 price war, compounded GLP-1, biosimilar litigation, commercialization failure, reimbursement failure, and device safety as RedTeam gates or caps.

## Verification

Commands run:

```bash
PYTHONPATH=src python -m unittest tests.test_round99_r7_loop5_biotech_healthcare_device -v
PYTHONPATH=src python -m e2r.cli.build_round99_r7_loop5_report
```

Both completed successfully before the full repository test run.
